The CHRU Team

Principal investigators (PIs)

Dr Noluthando Mwelase

Dr Noluthando Mwelase is a CHRU investigator in NIH and pharmaceutical-funded clinical trials with a core focus on HIV, HIV co-infections, HIV prevention, TB and COVID-19. She is committed to scientific research to improve the standard of treatment in poorly resourced settings. Her research includes the INSIGHT START study, ACTG neurology in HIV-positive participants, ART for the prevention of HIV, the treatment of advanced AIDS-associated Kaposi Sarcoma in resource-limited settings and the prevention of HIV-related TB. Dr Mwelase’s research also focuses on supporting those at the highest risk group of new HIV infections in South Africa, namely, adult girls and young women who account for more than half of CHRU’s clinical trial participants. She also participated as an investigator on clinical trials that tested the safety and efficacy of COVID-19 vaccines. Dr Mwelwase is currently an A5343 protocol team member.

Other members